Thioredoxin prolongs survival of B-type chronic lymphocytic leukemia cells

Blood

Volumn 95, Issue 4, 2000, Pages 1420-1426

  Nilsson, Joacim ^b   Söderberg, Ola ^b   Nilsson, Kenneth ^b   Rosén, Anders ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN BCL 2; THIOREDOXIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; APOPTOSIS; ARTICLE; CELL SURVIVAL; CELL VIABILITY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0343339955     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.4.1420.004k12_1420_1426     Document Type: Article

References (58)

1. Nilsson K. The control of growth and differentiation in chronic lymphocytic leukemia (B-CLU) cells. In Cheson BD, ed. Chronic Lymphocytic Leukemia. Scientific Advances and Developments. New York, NY: Marcel Dekker; 1992:33.
2. Foon KA. Chronic lymphoid leukemias: recent advances in biology and therapy. Stem Cells. 1995;13:1.
3. Rozman C, Monserrat E. Chronic lymphocytic leukemia. N Engl J Med. 1995;333:1052.
4. Caligaris-Cappio F. B-chronic lymphocytic leukemia: a malignancy of anti-self B cells. Blood. 1996;87:2615.
5. Alfarano A, Indraccolo S, Circosta P, et al. An alternatively spliced form of CD79b gene may account for altered B-cell receptor expression in B-chronic lymphocytic leukemia. Blood. 1999;93: 2327.
6. Schena M, Larsson LG, Gottardi D, et al. Growth and differentiation-associated expression of bcl-2 in B-chronic lymphocytic leukemia cells. Blood. 1992;79:2981.
7. Hanada M, Delia D, Aiello A, Stadmauer E, Reed JC. bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood. 1993;82:1820.
8. Dancescu M, Rubio-Trujillo M, Biron G, Bron D, Delespesse G, Sarfati M. Interleukin 4 protects chronic lymphocytic leukemia B cells from death by apoptosis and upregulates Bcl-2 expression. J Exp Med. 1992;176:1319.
9. Jewell AP, Worman CP, Lydyard PM, Yong KL, Giles FJ, Goldstone AH. Interferon-alfa up-regulates bcl-2 expression and protects B-CLL cells from apoptosis in vitro and in vivo. Br J Hematol 1994;88:268.
10. Buschle M, Campana D, Carding SR, Richard C, Hoffbrand AV, Brenner MK. Interferon y inhibits apoptotic cell death in B cell chronic lymphocytic leukemia. J Exp Med. 1993;177:213.
11. König A, Menzel T, Lynen S, et al. Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in B cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosis. Leukemia. 1997;11:258.
12. Osorio LM, De Santiago A, Aguilar-Santelises M, Mellstedt H, Jondal M. CD6 ligation modulates the Bcl-2/Bax ratio and protects chronic lymphocytic leukemia B cells from apoptosis induced by anti-lgM. Blood. 1997;89:2833.
13. McConkey DJ, Aguilar-Santelises M, Hartzell P, et al. Induction of DNA fragmentation in chronic B-lymphocytic leukemia cells. J Immunol. 1991; 146:1072.
14. Fluckiger AC, Durand I, Banchereau J. Interleukin 10 induces apoptotic cell death of B-chronic lymphocytic leukemia. J Exp Med. 1994;179:91.
15. Carlsson M, Tötterman TH, Rosén A, Nilsson K. IL-2 and a T cell hybridoma (MP6)-derived B cell stimulatory factor act synergistically to induce proliferation and differentiation of human B-chronic lymphocytic leukemia cells. Leukemia. 1989;3:593.
16. Carlsson M, Sundström C, Bengtsson M, Tötterman TH, Rosén A, Nilsson K. Interleukin 4 strongly augments or inhibits DNA synthesis and differentiation of B-chronic lymphocytic leukemia cells depending on the co-stimulatory activation and progression signals. Eur J Immunol. 1989;19: 913.
17. Cordingley FT, Bianchi A, Hoffbrand AV, et al. Tumour necrosis factor as an autocrine tumour growth factor for chronic B-cell malignancies. Lancet. 1988;1:969.
18. Larsson L-G, Carlsson M, Schena M, Lantz M, Caligaris-Cappio F, Nilsson K. Interleukin 2 enhances the production of tumor necrosis factor-a in activated B-type chronic lymphocytic leukemia (B-CLL) cells. Leukemia. 1993;7:226.
19. Rosén A, Lundman P, Carlsson M, et al. A CD4 + T-cell line-secreted factor, growth promoting for normal and leukemic B cells, identified as thioredoxin. Int Immunol. 1995;7:625.
20. Söderberg O, Christiansen I, Carlsson M, Nilsson K. Differences between B-CLL and normal B cells in their response to IL-2 (Thioredoxin + IL-2) and to CD40 ligation. Scand J Immunol. 1997;45:706.
21. Cantwell M, Hua T, Pappas J, Kipps TJ. Acquired CD-40 ligand deficiency in chronic lymphocytic leukemia. Nat Med. 1997;3:984.
22. Wendel-Hansen V, Sällström J, De Campos-Lima P, et al. Epstein-Barr virus (EBV) can immortalize B-CLL cells activated bycytokines. Leukemia. 1994;8:476.
23. Powis G, Briehl M, Oblong J, Redox signaling and the control of cell growth and death. Pharmacol Ther. 1995;68:149.
24. Nakamura H, Nakamura K, Yodoi J. Redox regulation of cellular activation. Annu Rev Immunol. 1997;15:351.
25. Holmgren A. Thioredoxin. Annu Rev Biochem. 1985;54:753.
26. Holmgren A, Björnstedt M. Thioredoxin and thioredoxin reductase. Meth Enzymol. 1995;252: 199.
27. Wollman EE, d'Auriol L, Rimsky L, et al. Cloning and expression of a cDNA for human Trx. J Biol Chem. 1988;263:15,506.
28. Tagaya Y, Maeda Y, Mitsui A, Wakasugi H, Yodoi J. ATL-derived factor (ADF), an IL-2 receptor/Tac inducer homologous to Trx; possible involvement of thiol reduction in the IL-2 receptor induction. EMBO J. 1989;8:757.
29. Silberstein DS, Ali MH, Baker SL, David JR. Human eosinophil cytotoxicity-enhancing factor: purification, physical characteristics, and partial amino acid sequence of an active polypeptide [erratum appears in J Immunol. 1991;15:147]. J Immunol. 1989;143:979.
30. Bertini R, Howard OMZ, Dong H-F, et al. Thioredoxin, a redox enzyme released in infection and inflammation, is a unique chemoattractant for neutrophils, monocytes, and T cells. J Exp Med. 1999;189:1.
31. Schenk H, Vogt M, Droge W, Schulze-Osthoff K. Thioredoxin as a potent costimulus of cytokine expression. J Immunol. 1996;156:765
32. Baker A, Payne CM, Briehl MM, Powis G. Thioredoxin, a gene found overexpressed in human cancer, inhibits apoptosis in vitro and in vivo. Cancer Res. 1997;57:5162.
33. Ericsson M, Hörling J, Wendel-Hansen V, Holmgren A, Rosén A. Secretion of thioredoxin after in vitro activation of human B cells. Lymphokine Cytokine Res. 1992;11:201.
34. Schmid C, lsaacsson PG. Proliferation centers in B-cell malignant lymphoma, lymphocytic (B-CLL): an immunophenotypic study. Histopathology. 1994;24:445.
35. Hariharan J, Hebbar P, Ranie J, Philomena A, Sinha M, Datta S. Alternative forms of the human thioredoxin mRNA: identification and characterization. Gene. 1996;173:265.
36. Ren X, Björnstedt M, Shen B, Ericsson ML, Holmgren A. Mutagenesis of structural half-cystein residues in human thioredoxin and effects on the regulation of activity by selenodiglutathione. Biochemistry. 1993;32:9701.
37. Hotz MA, Gong J, Traganos F, Darzynkiewicz Z. Flow cytometric detection of apoptosis: comparison of the assays of the in situ DNA degradation and chromatin changes. Cytometry. 1994;15:237.
38. Sander B, Andersson J, Andersson U. Assessment of cytokines by immunofluorescence and the paraformaldetiyde-saponin procedure. Immunol Rev. 1991;119:65.
39. Sahaf B, Söderberg A, Spyrou G, et al. Thioredoxin expression and localization in human cell lines: detection of full-length and truncated species. Exp Cell Res. 1997;236:181.
40. Söderberg A, Sahaf B, Holmgren A, Rosén A. Monoclonal antibodies to human thioredoxin reductase. Biochem Biophys Res Commun. 1998; 249:86.
41. Rosén A, Uggla C, Szigeti R, Kallin B, Lindqvist C, Zeuthen J. AT-helper cell x Molt4 human hybridoma constitutively producing B-cell stimulatory and inhibitory factors. Lymphokine Res. 1986;5:185.
42. Peng M, Lundgren E. Transient expression of Epstein-Barr virus LMP1 gene in B-cell chronic lymphocytic leukemia cells, T cells, and hematopoietic cell lines: cell dependent and independent induction of CD23, CD21, and ICAM-1. Leukemia. 1993;7:104.
43. Kitada S, Andersen J, Akar S, et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood. 1998;91:3379.
44. Pepper C, Hoy T, Bentley DP. Bcl-2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance. Br J Cancer 1997;76:935
45. Buttke TM, Sandslrom PA. Oxidative stress as a mediator of apoptosis. Immunol Today. 1994;15: 753.
46. Korsmeyer SJ, Yin XM, Oltvai ZN, Veis-Novack DJ, Linette GP. Reactive oxygen species and the regulation of cell death by the Bcl-2 gene family. Biochem Biophys Acta. 1995;1271:63.
47. ci Celle PF, Mariana S, Riera L, Staccini A, Reato G, Foa R. Interleukin-8 induces the accumulation of B-cell chronic lymphocytic leukemia cells by prolonging survival in an autocrine fashion. Blood. 1996;87:4382.
48. Fountoulakis M. Unfolding intermediates of the extracellular domain of the interferon gamma receptor. J Biol Chem. 1992;267:7095.
49. Nathens AB, Bitar R, Watson RWG, et al. Thiol-mediated regulation of ICAM-1 expression in endotoxin-induced acute lung injury. J Immunol. 1998;160:2959.
50. Reiter C. Cluster report: CD6. In Knapp W, Dörken B, Gilks WR, et al, eds. Leukocyte Typing IV. White Cell Differentiation Antigens. New York, NY: Oxford; 1989:339.
51. Jin DY, Chae HZ, Rhee SG, Jeang KT. Regulatory role for a novel human thioredoxin peroxidase in NF-κ B activation. J Biol Chem. 1997; 272:30,952.
52. Saitoh M, Nishitoh H, Fujii M, et al. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J. 1998;17: 2596.
53. Go T, Isowa N, Hirata T, Yodoi J, Hitomi S, Wada H. Thymic interdigitating cells express thioredoxin (TRX/ADF): an immunohistochemical study of 82 thymus and thymoma samples. Thymus. 1997; 24:157.
54. Dean MF, Martin H, Sansom G. Characterization of a thioredoxin-related surface protein. Biochem J. 1994;304:861.
55. Gibson LF, Piktel D, Narayanan R, Nunez G, Landreth KS. Stromal cells regulate bcl-2 and bax expression in pro-B cells. Exp Hematol. 1996;24: 628.
56. + tonsillar plasma cells are rescued from apoptosis by bone marrow fibroblasts. J Exp Med. 1996;183:227.
57. Tötterman TH, Carlsson M, Simonsson B, Bengtsson M, Nilsson K. T-cell activation and subset patterns are altered in B-CLL and correlate with the slage of the disease. Blood. 1989; 74:786.
58. Gordon J, Åman P, Rosén A, Ernberg I, Ehlin-Henriksson B, Klein G. Capacity of B lymphoblastoid lines of diverse tumor origin to produce and respond to B cell growth factors. Int J Cancer. 1985;35:251.